IntelliCyt raises $7.4M

What does IntelliCyt do?

IntelliCyt, is a leading provider of integrated platform for accelerating discovery, immunology and antibody discovery. The company develops and markets high throughput cell and bead based screening solutions for using life sciences. The company uses proprietary technologies for creating instrumentation, software products and reagent kits which dramatically increase the speed and decreases the price of detecting and measuring beads and cells. The company’s products address a pervasive need among biotechnology, pharmaceutical and life sciences research labs for achieving increased productivity while getting used to the accelerating pace and increasing the modern life sciences complexity.

How much IntelliCyt was founded?

IntelliCyt raised $7.4M in Venture round on October 22^nd, 2015 from New Mexico Community Capital, Prolog VenturesVerge Fund and Arboretum Ventures.

Previous funding

• $8M in undisclosed round on May 6^th, 2013 from Arboretum Ventures, Prolog Ventures. New Mexico Community Capital and Verge Fund
• $4M in Debt Financing on June 10^th, 2014 from Oxford Finance Corporation
• $5.44 M in undisclosed round on July 28, 2015

What is next for IntelliCyt?

IntelliCyt is rapidly growing and the latest funding will be used for continuing scaling the company’s commercial efforts all over the world and expanding their product offerings for rapidly accelerating markets including the Immuno-oncology department. The company is experiencing rapid sales growth and this funding positions the company to accelerate the growth and enhance the position as a leading provider of next gen platform for cell and bead based analyses for optimizing breakthrough therapies for precision medicine.

More about IntelliCyt

IntelliCyt was founded in 2006 by R. Terry Dunlay. It has its headquarters in Albuquerque, NM.  The company was founded by leading scientists and life science entrepreneurs. It develops innovative tools for facilitating the study of cells and components of cells, for gaining a better understanding of normal and disease processes.